prikaz prve stranice dokumenta Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Pregledni rad
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
Basic & Clinical Pharmacology & Toxicology, 123 (2018), 4; 509-518. https://doi.org/10.1111/bcpt.13035
Vrkić Kirhmajer, Majda; Macolić Šarinić, Viola; Šimičević, Livija; Ladić, Iva; Putarek, Krešimir; Banfić, Ljiljana; Božina, Nada

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Vrkić Kirhmajer, M., Macolić Šarinić, V., Šimičević, L., Ladić, I., Putarek, K., Banfić, Lj. i Božina, N. (2018). Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile. Basic & Clinical Pharmacology & Toxicology, 123. (4), 509-518. doi: 10.1111/bcpt.13035

Vrkić Kirhmajer, Majda, et al. "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile." Basic & Clinical Pharmacology & Toxicology, vol. 123, br. 4, 2018, str. 509-518. https://doi.org/10.1111/bcpt.13035

Vrkić Kirhmajer, Majda, Viola Macolić Šarinić, Livija Šimičević, Iva Ladić, Krešimir Putarek, Ljiljana Banfić i Nada Božina. "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile." Basic & Clinical Pharmacology & Toxicology 123, br. 4 (2018): 509-518. https://doi.org/10.1111/bcpt.13035

Vrkić Kirhmajer, M., et al. (2018) 'Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile', Basic & Clinical Pharmacology & Toxicology, 123(4), str. 509-518. doi: 10.1111/bcpt.13035

Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić Lj, i sur.. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile. Basic & Clinical Pharmacology & Toxicology [Internet]. 2018. [pristupljeno 29.11.2024.];123(4):509-518. doi: 10.1111/bcpt.13035

M. Vrkić Kirhmajer, et al., "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile", Basic & Clinical Pharmacology & Toxicology, vol. 123, br. 4, str. 509-518, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:203793. [Citirano: 29.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:203793
Podaci o radu
Naslov (engleski)Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
AutorMajda Vrkić Kirhmajer
MBZ: 319133
AutorViola Macolić Šarinić
MBZ: 188196
AutorLivija Šimičević
MBZ: 384903
AutorIva Ladić
AutorKrešimir Putarek
MBZ: 238462
AutorLjiljana Banfić
MBZ: 224315
AutorNada Božina
MBZ: 91773
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (WHO) adverse drug reaction (ADR) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug-drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87-year-old female Croatian/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles CYP2C9*1/*3, CYP3A4*1/*22, CYP3A5*3/*3, CYP2D6*1/*4, UGT1A1*28/*28, UGT2B7 -161C/T, ABCB1 3435C/T and ABCB1 1237C/T which could have added to the interactions not only between ticagrelor and rosuvastatin but also other concomitantly prescribed medicines, such as amiodarone and proton pump inhibitors. In this case report, the possible multifactorial causes for rhabdomyolysis following concomitant use of rosuvastatin and ticagrelor such as old age, polypharmacy, renal impairment, along with pharmacogenetics will be discussed
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBasic & Clinical Pharmacology & Toxicology
Brojčani podacivol. 123, br. 4, str. 509-518
p-ISSN1742-7835
DOIhttps://doi.org/10.1111/bcpt.13035
URN:NBNurn:nbn:hr:184:203793
Datum objave publikacije2018
URL dokumentahttp://bib.irb.hr/1050352
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-08 11:27:56